

United States Patent and Trademark Office

W

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

Г	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	10/021,312	12/19/2001	Suzie Hwang Pun	CTCH-P01-013	9391	
	28120 7590 05/18/2005			EXAMINER		
		FISH & NEAVE IP GROUP			PUTTLITZ, KARL J	
	ROPES & GRA	AY LLP				
	ONE INTERNATIONAL PLACE			ART UNIT	PAPER NUMBER	
	BOSTON, MA	A 02110-2624		1621		

DATE MAILED: 05/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/021,312	PUN ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Karl J. Puttlitz	1621			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	·					
1)⊠	1) Responsive to communication(s) filed on 28 February 2005.					
2a) <u></u> □	This action is FINAL . 2b)⊠ This	action is non-final.				
3) 🗌	Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is			
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Dispositi	on of Claims					
5)⊠ 6)⊠ 7)⊠	Claim(s) 1-11,13-16,18-20 and 24-31 is/are per 4a) Of the above claim(s) 1-11 and 13 is/are with Claim(s) is/are allowed. Claim(s) 14-1618 is/are rejected. Claim(s) 20 and 29-31 is/are objected to. Claim(s) are subject to restriction and/o	thdrawn from consideration.				
Applicati	ion Papers					
9)	The specification is objected to by the Examine	r.				
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority (under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
A44 - 1						
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice 3) Information	te of References Cited (PTO-032) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date	Paper No(s)/Mail Da				

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/28/2005 has been entered.

The outstanding rejections under section 112, first paragraph are withdrawn. Specifically, in view of the level of skill in the art, along with the guidance in the specification, those of ordinary skill would not require undue experimentation to select appropriate cyclodextrin polymers, inclusion complexes and therapeutic agents. In this same vein, applicant indeed posses these elements based on the description in the specification, and the level of skill in the art.

The outstanding rejection under section 103 is withdrawn since Argawl fails to provide any motivation to modify its disclosure to include compositions comprising polymers of cyclodextrin.

Application/Control Number: 10/021,312

Art Unit: 1621

The following is new ground of rejection:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 14-16, 18, 19 and 22-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/47172 (WO 172).

The claims are drawn to, inter alia, a method of preparing a composition, comprising combining a therapeutic agent, a cyclodextrin-containing polmer having host and/or guest functionality, and a complexing agent to form the composition, wherein said cyclodextrin-containing polymer and said complexing agent form an inclusion complex, and said therapeutic agent, polymer, and complexing agent are separate molecules.

WO 172 teaches pharmaceutical compositions for oral administration comprising cyclodextrines and therapeutic agents. See pages 4 and 5.

Wo 172 fails to explicitly teach the physical characteristics of the composition set forth in the dependant claims. However, WO 172 substantially teaches the compositions set forth in the claims, and therefore, absent any objective evidence to the contrary, the physical characteristics of the compositions are within the motivation of those of ordinary skill, and therefore, prima facie obvious.

Application/Control Number: 10/021,312 Page 4

Art Unit: 1621

Claim Objections

Claims 20 and 29-31 are allowable outside of dependence on a rejected claims.

Therefore these claims would be allowable if rewritten in independent form and including all of the features of any intervening claim.

Page 5

Application/Control Number: 10/021,312

Art Unit: 1621

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karl J. Puttlitz whose telephone number is (571) 272-0645. The examiner can normally be reached on Monday to Friday from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter, can be reached at telephone number (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karl J. Puttlitz Assistant Examiner

Johann R. Richter, Ph.D., Esq. Supervisory Patent Examiner

Biotechnology and Organic Chemistry

Art Unit 1621 (571) 272-0646